Triple Pointome VCT (LSE:TPVA) Research & Development: £0.00 Mil (TTM As of Sep. 2022)


What is Triple Pointome VCT Research & Development?

Triple Pointome VCT LSE:TPVA 28 Research & Development is £0.00 Mil as of Sep. 2022. GuruFocus rates LSE:TPVA with a GF Score™ of 28/100. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Triple Pointome VCT's Research & Development for the six months ended in Sep. 2022 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2022 was £0.00 Mil.

Triple Pointome VCT  (LSE:TPVA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Triple Pointome VCT Research & Development Related Terms

Triple Pointome VCT Research & Development Historical Data

* Premium members only.

The historical data trend for Triple Pointome VCT's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Triple Pointome VCT Research & Development Chart

Triple Pointome VCT Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Triple Pointome VCT Semi-Annual Data
Mar13 Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Triple Pointome VCT Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
Triple Pointome VCT (LSE:TPVA) has a Research & Development of £0.00 Mil as of Sep. 2022. Research and development expense is the total cost for research and development activities. View historical data on Triple Pointome VCT and its competitors.
Is Triple Pointome VCT's Research & Development too high?
Triple Pointome VCT's current Research & Development is £0.00 Mil. Overall, Triple Pointome VCT has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Triple Pointome VCT's Research & Development compare to MTR?
Triple Pointome VCT's Research & Development of £0.00 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Asset Management company?
A good Research & Development depends on the Asset Management industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Triple Pointome VCT and its competitors. Triple Pointome VCT's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Triple Pointome VCT stock overvalued right now?
Triple Pointome VCT (LSE:TPVA) has a current Research & Development of £0.00 Mil. The current Research & Development is £0.00 Mil. Triple Pointome VCT's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Triple Pointome VCT (LSE:TPVA), the current Research & Development is £0.00 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Triple Pointome VCT Business Description

Address 1 King William Street, London, GBR, EC4N 7AF
Triple Point Income VCT PLC is a part of the financial services domain in the United Kingdom. It is a venture capital trust formed with the objective of capital preservation and payment of regular tax-free dividends to investors. The company's mission comprises three priorities, which are capital security, liquidity, and predictable returns. It has chosen to focus its investing activities towards companies involved in renewable energy, energy production, innovative vertical growing, and SME funding.